Hyponatremia in Heart Failure: Pathogenesis and Management

Mario Rodriguez¹, ⁶, #, Marcelo Hernandez¹, #, Wisit Cheungpasitporn², Kianoush B. Kashani³, ⁴, Iqra Riaz⁵, Janani Rangaswami⁵, Eyal Herzog⁶, Maya Guglin⁷ and Chayakrit Krittanawong¹, ⁶, *

¹Department of Internal Medicine, Icahn School of Medicine at Mount Sinai St Luke and Mount Sinai West, New York, NY, USA; ²Division of Nephrology, Department of Internal Medicine, University of Mississippi Medical Center, Jackson, Mississippi, MS, USA; ³Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, MN, USA; ⁴Division of Pulmonary and Critical Care Medicine, Department of Medicine, Mayo Clinic, Rochester, MN, USA; ⁵Department of Nephrology, Einstein Medical Center, Philadelphia, PA, USA; ⁶Cardiac Intensive Care Unit, Mount Sinai St Luke, Mount Sinai Heart, New York, NY, USA; ⁷Division of Cardiology, Mechanical Assisted Circulation, Gill Heart Institute, University of Kentucky, Kentucky, KY, USA

Abstract: Hyponatremia is a very common electrolyte abnormality, associated with poor short- and long-term outcomes in patients with heart failure (HF). Two opposite processes can result in hyponatremia in this setting: Volume overload with dilutional hypertensive hyponatremia from congestion, and hypovolemic hyponatremia from excessive use of natriuretics. These two conditions require different therapeutic approaches. While sodium in the form of normal saline can be lifesaving in the second case, the same treatment would exacerbate hyponatremia in the first case. Hypovolemic hyponatremia in HF patients is multifactorial and occurs mainly due to the persistent release of arginine vasopressin (AVP) in the setting of ineffective renal perfusion secondary to low cardiac output. Fluid restriction and loop diuretics remain mainstay treatments for hypovolemic/dilutional hyponatremia in patients with HF. In recent years, a few strategies, such as AVP antagonists (Tolvaptan, Conivaptan, and Lixivaptan), and hypertonic saline in addition to loop diuretics, have been proposed as potentially promising treatment options for this condition. This review aimed to summarize the current literature on pathogenesis and management of hyponatremia in patients with HF.

Keywords: Hyponatremia, sodium, heart failure, congestive heart failure, vaptans, pathogenesis.

1. INTRODUCTION

Despite advances in medicine, heart failure (HF) remains one of the most common principal diagnoses for hospital admission worldwide [1-5]. In the United States (U.S.), total costs, including indirect costs for HF, are estimated to increase from $31 billion in 2012 to $70 billion in 2030 [6]. Patients with chronic HF are well known to have neurohormonal abnormalities including activations of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS), which commonly lead to derangements in electrolytes and acid-base balance [7, 8]. In addition to patient’s functional impairment, these metabolic abnormalities such as hyponatremia, hypochloremia and hypokalemia have been considered as poor prognostic indicators of all-cause mortality in HF patients [9-11].

Hyponatremia, defined as a serum sodium concentration <135 mEq/L, is the most common electrolyte abnormality in the hospitalized patients associated with a prolonged hospital length of stay, and higher risks of readmission and mortality [12-14]. We analyzed the ESCAPE Trial analysis and found a benign nature of mild hyponatremia on discharge in HF patients with normal admission Na [15]. In fact, depending on the patient population, the prevalence of hyponatremia in HF patients ranges between 11% and 27% [10, 16-22]. In addition to being well demonstrated in general patient population [23], the presence of hyponatremia on or after admission in patients with HF is also associated with increased risk of morbidities (i.e., falls and bone fractures), discharge to acute care facilities, longer hospital stays, and mortality [23-25]. Furthermore, studies have shown that HF patients with hyponatremia were more likely to be admitted to the ICU reflecting the severity of HF and/or the direct effect of hyponatremia [11, 26]. Among patients with HF, persistent hyponatremia after hospitalization has been shown to be associated with a 1.5 to 1.7-fold increase risk of 30-day readmission or mortality [24, 27].
In the U.S., the direct medical costs of hyponatremia have been estimated between $1.6 billion and $3.6 billion [14, 28]. This review aimed to present the current literature and future directions regarding the pathogenesis and management of hyponatremia in patients with HF.

2. HYPERVOLEMIC HYPONATREMIA

Hyponatremia in patients with HF can be multifactorial as summarized in Table I [8, 11, 12, 18, 25, 26, 29-32]. The main mechanisms of hyponatremia in HF include 1) adaptive neurohormonal activation with a predominance and leading role of arginine vasopressin (AVP) (dilution state); 2) potent thirst stimulation from both low cardiac output and angiotensin II, and 3) free water retention in the setting of severely reduced glomerular filtration rate (GFR).

2.1. Neurohormonal Activation in Dilutional Hyponatremia

AVP is synthesized in the supraoptic and paraventricular nuclei of the anterior hypothalamus [33]. Through axonal transport, AVP is transported into nerve terminals within the posterior lobe of the pituitary gland and then released into the bloodstream in response to hypertonicity [34]. AVP secretion is increased by two different stimuli: baroreceptor activation and decreased effective circulating volume [33]. Arterial underfilling from the reduced cardiac output along with activation of the sympathetic nervous system and renin-angiotensin-aldosterone system (RAAS) lead to increased release of AVP. AVP binds to the vasopressin 2 (V2) receptor in the collecting ducts of the nephron and via a cyclic guanosine monophosphate (GMP) mediated mechanism increases aquaporin-2 water channel expression on the luminal side. This, in turn, leads to increased permeability of water in the collecting ducts and enhanced free water retention [34].

In the usual state of health, AVP is degraded and excreted by the liver and kidneys rapidly. At low levels, AVP also stimulates V1a receptors in the liver, vasa recta, and collecting ducts increasing the hypertonicity in the renal medulla through urea production in the liver, urea reabsorption in the collecting duct and by decreasing flow through the vasa recta. When vasa recta receive high flow, interstitial tonicity reduces by washout of osmoles in the medulla [35].

In patients with HF, the reduction in cardiac output induces activation of the sympathetic nervous system [8]. The peripheral vasoconstriction instigated by this phenomenon coupled with the reduced cardiac output leads to sodium and water retention as well as RAAS activation [5, 9]. RAAS activation can increase angiotensin II levels, leading to thirst stimulation and worsening hyponatremia in patients with HF. Compared with patients without HF, AVP levels are higher in patients with severe HF [33], which does not appropriately decrease even with acute water loading [36, 37], thus results in hyponatremia [29, 34, 36] (Fig. 1). AVP role in acute HF and hyponatremia is crucial since it has been shown that HF patients exhibit not only increased AVP production but also a dysregulation of AVP characterized by an elevation of its levels despite the presence of volume overload, atrial distension, and low plasma osmolality [36, 38-40].

2.2. Increase Free Water Consumption in the Setting of Low GFR

Cardiorenal syndrome (CRS) encompasses a disorder of the heart and kidneys whereby acute or chronic dysfunction in one organ may induce acute or chronic dysfunction in the other organ [41]. The Acute Dialysis Quality Initiative outlined a consensus approach in 2008 which phenotyped CRS into two major groups: cardio-renal and reno-cardiac syndromes, based on the *primum movens* of the disease process [42]. This was further grouped into five subtypes of the cardio-renal syndromes based on disease acuity and sequential organ involvement, which are outlined in Table 2. Over 40% of HF patients had some degree of renal impairment (cardio-renal syndrome) [3]. Conversely, HF is highly prevalent approximately up to 60% in patients with advanced CKD and end-stage renal disease (reno-cardiac syndrome) [43]. In patients with CRS, hyponatremia can be dilutional, due to excess water or hypotonic fluid intake or impaired free water clearance in the setting of elevated AVP levels and reduced GFR [44].

2.3. Depletion Induced Hyponatremia

Diuretics are one of the most common reasons for drug-induced hyponatremia (Table 1). This is particularly charac-

| Causes of Hyponatremia in Patients with Heart Failure |  |
|---|---|
| 1. Continued release AVP despite a reduction in osmolality due to the following reasons: |  |
| • Low cardiac output |  |
| • Decreased renal blood flow |  |
| • Reduced baroreceptor stimulation mediated by low blood pressure |  |
| 2. Low cardiac output leads to activation of RAAS and increase in angiotensin II levels, potent stimuli to thirst, resulting in enhanced water intake |  |
| 3. Medications used to treat heart failure, hypertension, or cardiac-related conditions |  |
| • Diuretics (especially thiazides, less commonly aldosterone antagonists, amiloride, loop diuretics) |  |
| 4. Hyponatremia in the setting of advanced CKD/ESRD due to Cardiorenal syndromes |  |
| • Hypotonic hyponatremia due to increased free water intake in the setting of low GFR |  |

**Abbreviations:** ACEIs, Angiotensin-Converting Enzyme Inhibitors; AVP, Arginine Vasopressin; CKD, Chronic Kidney Disease; ESRD, End-Stage Renal Disease; GFR, Glomerular Filtration Rate; RAAS, Renin-Angiotensin-Aldosterone System.
teristic of thiazide diuretics because they work entirely in the distal tubules and do not interfere with urinary concentrating capacity and the action of AVP to promote water retention [45, 46]. Diuretic-induced hyponatremia is usually mild, but idiosyncratic reactions have been reported [31, 32]. Thiazides more commonly cause hyponatremia compared to loop diuretics, with a thiazide-induced hyponatremia incidence that ranging 4.1-14 % [46]. Female gender, advanced age, low body mass, multiple comorbidities and increasing dosage of thiazides are risk factors for hyponatremia from this drug class. Thiazides have more propensity to cause hyponatremia because of inhibition of urinary dilution through decreased sodium-chloride re-absorption in the distal tubule, a mechanism that loop diuretics do not have. In general, the pathophysiological factors implicated in thiazide-induced hyponatremia are increased water intake from AVP stimulation through thirst from water loss, reduced free water clearance from antidiuretic hormone (ADH) stimulus and as mentioned above, renal sodium/potassium loss.

Although less commonly, loop diuretics can also contribute to hypovolemic hyponatremia. According to the Acute Decompensated Heart Failure National Registry (ADHERE) registry, loop diuretics are utilized in up to 88% of HF patients as the mainstay of management [47]. Following management of acute HF decompensation, up to 70% of patients continue loop diuretics chronically [47, 48]. Loop diuretics

Table 2. Summary of cardio-renal syndromes (CRS) phenotypes [117].

| CRS Type | Denomination     | Description                                                                 | Model                                      |
|----------|------------------|----------------------------------------------------------------------------|--------------------------------------------|
| I        | Acute Cardio-renal | Acute cardiac decompensation leads to acute kidney injury which can be reversible | Acute coronary syndrome/acute HF triggering acute kidney failure |
| II       | Chronic Cardio-renal | Chronic cardiac dysfunction leads to progressive chronic kidney dysfunction which is mostly irreversible | Chronic heart failure causing chronic kidney disease |
| III      | Acute Reno-cardiac    | Abrupt primary kidney dysfunction leads to acute cardiac dysfunction       | Acute glomerulonephritis instigating acute HF |
| IV       | Chronic Reno-cardiac  | Primary kidney dysfunction leads to cardiac impairment                      | Chronic kidney disease causing coronary artery disease/diastolic heart dysfunction |
| V        | Secondary Cardio-renal | Acute/chronic systemic disease leading to combined cardiac and kidney dysfunction | Sepsis, vasculitis, diabetes mellitus, amyloidosis |
block the sodium-potassium-chloride cotransporter in the thick ascending limb of the loop of Henle [48]. This part of the nephron makes a substantial contribution to the tonicity of the renal interstitium. Loop diuretics interfere with the concentrating capacity of kidneys which leads to reduced free water reabsorption that in turn leads to the production of hypotonic urine [47]. Nevertheless, if profound volume depletion with robust neurohormonal activation ensues, water diuresis will be less pronounced leading to decreased glomerular filtration rate and distal nephron flow in the setting of increased AVP levels, which constitutes an ideal scenario for hyponatremia development [49].

Addition of thiazides (e.g., metolazone or chlorothiazide) to loop diuretics, so-called sequential nephron blockade has been shown to be an effective approach to overcome diuretic resistance in patients with HF [50, 51]. However, this combination of diuretic therapy can result in significant electrolyte abnormalities including hypokalemia, hyponatremia, and hypochloremic metabolic alkalosis [51, 52]. Hyponatremia can occur in this setting because the increase in urine sodium excretion is much higher than the increase in urine water excretion, resulting in more hypertonic urine after sequential nephron blockade than after treatment with loop diuretics alone [51, 53].

Aldosterone antagonist such as spironolactone, work by blocking reabsorption of sodium in the distal convoluted tubules and collecting ducts, generating less hypotonic urine. Their use in heart failure with reduced ejection fraction is usually after betablocker and ACEI have been started. In a retrospective study by Goland et al. [54] they analyzed 157 patients of whom 100 were given spironolactone (were already on ACEI and betablocker). At 1 year follow up, 6 patients developed hyperkalemia and 2 patients developed hyponatremia [54].

2.4. Management of Hyponatremia

Management of hyponatremia, in general, represents a challenge, especially for the patient with expanded extracellular volume. In patients that are admitted with acute HF exacerbation, the concomitant presence of hyponatremia on admission has shown to be associated with higher all-cause and cardiovascular mortality, especially when there is a further decrease in the sodium level during the hospitalization [55]. Currently, there are no specific guidelines for the management of hyponatremia in the setting of HF; data from a U.S. registry shows that the most commonly used treatment modalities for hyponatremia in HF are fluid restriction, and non-specific management strategies including diuretic therapy for congestion along with isotonic or hypotonic saline, or V2 receptor antagonists [55].

2.5. Hyponatremia with Severe Symptoms

The initial management of the patient with hyponatremia should be guided by the severity of symptoms and the acuity of the hyponatremia [56, 57]. The most urgent complication of hyponatremia is cerebral edema [57]. Acute hyponatremia, defined as the one that develops in <48 hours, and can often present with neurological symptoms, given that there has been no time for counter-regulatory mechanisms to help abate its clinical impacts [56, 57]. These neurologic symp-
Proposed Treatment Options for HF Patients with Hyponatremia (Hyypervolemic Hyponatremia)

| Current Standard/Conventional Approaches |
|------------------------------------------|
| • Fluid restriction less than 800-1000 mL/day |
| • Loop diuretics |
| • Renal replacement therapy for cases diuretic resistance, advanced CKD/ESRD, severe AKI |

| Proposed/Possible Optional Approaches |
|---------------------------------------|
| • ACEIs |
| • AVP antagonists: Tolvaptan and Lixivaptan |
| • Hypertonic saline in addition to diuretics |

Abbreviations: ACEIs, Angiotensin-Converting Enzyme Inhibitors; AKI, Acute Kidney Injury; AVP, Arginine Vasopressin; CKD, Chronic Kidney Disease; ESRD, End-Stage Renal Disease.

Table 3. Summary of proposed treatment options for HF patients with hyponatremia [11, 21, 29, 38, 69, 70, 72, 73, 78, 80, 108].

| First Author | Treatment | Outcomes |
|--------------|-----------|----------|
| Albert et al. [70] | Fluid restriction (<800 ml/day) in hyponatremic patients with heart failure | Better quality of life at 60 days |
| Aliti et al. [118] | Fluid (<800 ml/day) and sodium (<800 mg /day) restriction in patients with acute heart failure | Nonstatistically significant decrease in rehospitalizations. Aggressive fluid and sodium restriction has no effect on weight loss or clinical stability. |
| Gheorghiade et al. [119] | Tolvaptan 30,45 or 60 mg vs. placebo | Normalization of serum sodium after 24 h, greater decrease in body weight and edema, increase urine output with tolvaptan |
| Gheorghiade et al. [120] | Tolvaptan 30,60 or 90 mg vs. placebo | Normalization of serum sodium with tolvaptan |
| Ghali et al. [121] | Conivaptan 40 or 80 mg vs. placebo | Normalization of serum sodium with conivaptan |
| Zelset et al. [122] | Conivaptan 40 or 80 mg vs. placebo | Increase in serum sodium concentration with conivaptan |
| Konstam et al. [123] | Tolvaptan 30 mg vs. placebo | No effect on mortality or hospitalization, significant increase in serum sodium with tolvaptan |
| Felker et al. [91] | Tolvaptan 30 mg vs. placebo added to furosemide | Greater weight loss and fluid loss, but no improvement in number of responders at 24 hrs |

Abbreviations: BID, twice (two times) a day; IV, Intravenous; vs., Versus.

to prominent gastrointestinal, or third-space losses [11]. These HF patients with volume depletion and concurrent hyponatremia can have a severely reduced effective circulating volume, especially with inadequate dietary intake of osmoles (protein and electrolytes) and use of thiazide diuretics [11]. In this setting, optimization of mean arterial pressure (MAP), in order to maintain adequate renal perfusion is suggested by withholding blood pressure lowering medications, and treatments to improve heart function by the use of inotropes [21, 26, 66, 67]. It is also suggested that hyponatremia in this setting (depletion induced hyponatremia) can potentially be improving with normal saline administration [11]. However, clinicians have to do a careful evaluation of the patient’s volume status, since intravenous fluids in patients with HF has never been shown to provide benefits and is associated with worse outcomes [57, 60, 68]. Independent of the pathophysiological mechanism, magnesium, and potassium deficiencies have to be corrected, and thiazide diuretics should be discontinued [11].

4. TREATMENT OF HYPERVOLEMIC HYponatremia

For hyervolemic hyponatremia (dilution), the mainstay of management is focused on fluid restriction, promoting free water excretion by increasing the distal nephron flow and lowering of AVP levels or its function (i.e., use of AVP receptor antagonists) [64, 65]. Tables 3 and 4 summarized the proposed treatments for hypervolemic hyponatremia in HF patients.

4.1. Fluid Restriction

Fluid restriction is helpful in the treatment of dilutional hyponatremia [69]. This approach has been studied in a randomized study allocating patients to a group with usual care vs. fluid restriction of <1L per day [70]. After 60 days, patients in the fluid restricted group had better scores of symptoms burden and overall quality of life [70]. In a small study, comparing fluid restriction vs. tolvaptan (a V2 receptor antagonist) in hyponatremic patients, the sodium level in-
creased by 1 mEq/L in the fluid restriction group at outpatient follow up (although the increase was greater in the tolvaptan arm) [71]. A clinically significant increase in serum sodium with water restriction alone might be difficult, and free water restriction is difficult to maintain following hospital discharge as patients with HF often have increased thirst [70, 72]. In most cases, however, more liberal fluid intake of 2L per day is appropriate.

4.2. Diuretics

An increase in distal nephron flow can be achieved with loop diuretics [49]. Loop diuretics will also decrease tonicity in the renal medulla and facilitate increased free water excretion. Loop diuretics represent the first line of management in dilutional hyponatremia of acute HF [11, 29, 36, 73, 74]. In the ESCAPE trial, we found that patients with ADHF and hyponatremia on admission had a higher degree of congestion and required higher doses of furosemide, compared with normonatremic subjects [75]. Interestingly, our group has shown that the association between the percentage increase in loop diuretic utilization in-hospital relative to baseline and the development of discharge hyponatremia [76]. Whether diuretics should be accompanied by hypertonic saline has been debated [77], since it is suggested that osmotic action of hypertonic saline administration can result in instantaneous mobilization of extravascular fluid into the intravascular space [77, 78]. Small studies in patients with severe refractory HF have shown that the addition of small-volume hypertonic saline to high dose furosemide can be well tolerated, can cause an increase in serum sodium, improve signs and symptoms of congestion, and has a reduction in readmission rate and mortality [77, 79]. However, the use of hypertonic saline in addition to diuretics for the sole management of hyponatremia in HF still requires validations in future studies. Currently, there is no evidence to support the use of hypertonic saline in HF patients with hyponatremia without neurological symptoms [55, 56]. When renal replacement therapy is indicated in subjects with diuretic refractoriness, advanced CKD or severe AKI, careful serial sodium monitoring during dialysis must be ensured to avoid rapid correction of serum sodium [80].

4.3. ACEI

Angiotensin-converting enzyme inhibitors (ACEI) help improve the hemodynamic perturbations intrinsic to CRS [81]. In addition, they have been shown to increase serum sodium level in patients with HF in small studies [82, 83]. This effect is likely due to enhanced cardiac output, and via their AVP antagonist activity in the collecting ducts, they increase the ability of the kidney to excrete diluted urine [33]. Thus, it is suggested that ACEI should be utilized in the admitted patients with HF who are also hyponatremic unless there are contraindications to their use [11]. However, in the long term, an analysis of the Italian HF registry showed that the use of ACEI did not modify the relationship between hyponatremia and 1-year mortality in HF patients [84].

4.4. AVP-receptor Antagonists

AVP antagonists (i.e., vaptans) were thought to be pathophysiologically promising in the management of HF and CRS, but evidence has shown otherwise [21, 60, 71]. AVP antagonists act on the collecting ducts of the distal nephrons by preventing aquaporin 2-channel availability in production [85]. Conivaptan is an intravenous aquaretic agent that inhibits both V1 and V2 receptors, whereas tolvaptan and lixivaptan are oral selective V2 receptor antagonist agents [64]. Vaptans increase plasma sodium levels without compromising the hemodynamics or impairing renal function [74, 81]. Regarding AVP receptors, cardiovascular, renal and other effects are mediated through 3 main receptors: V1A, V1B, V2. These receptors are G protein-coupled and they differ mainly by their second messenger mechanism. V1A receptor is coupled to a phosphoinositol (IP3) second messenger mechanism and is found mainly on vascular smooth muscle, myocardium and platelets, meaning activation mediates vasoconstriction in peripheral and coronary circulation as well as platelet aggregation [86]. Contrasting, V1B (sometimes referred to as V3) receptors are calcium and IP3 second messenger receptors that are mainly located in the anterior pituitary and mediate adrenocorticotropic hormone release. V2 receptors use cyclic adenosine monophosphate as a second messenger and are found on the collecting tubules of the kidney and mediate free water absorption [86].

Vaptans should be used carefully as they can cause xerostomia, polydipsia and sodium overcorrection. It is recommended that the therapy is initiated in the hospital at a lower dose with slow up-titration [64]. Fluids should not be restricted, and serum sodium should be monitored every 6-8 hours when vaptans are being used. Vaptans should not be used in patients with hypovolemic hyponatremia, and their effectiveness might be reduced in patients with renal failure [87]. Due to the risk of liver injury, FDA issued a warning to not administer vaptans for more than 30 days or in patients with the underlying chronic liver disease [88]. In general, the role of vaptans in hyponatremic patients with HF is limited mainly to patients who failed adequate correction with other medical management strategies.

4.5. Tolvaptan

In an investigation called “Study of Ascending Levels of Tolvaptan in Hyponatremia” (SALT-1 and -2), an improvement in serum sodium level and cognitive ability in the tolvaptan group in comparison with the control arm was reported, but only 30% of subjects had HF [87]. Several other studies have also shown improvement in serum sodium with the use of vaptans, but outcomes in the long term remained unknown [64, 74]. The EVEREST trial (efficacy of Vasopressin antagonism in HF outcome study with tolvaptan) was an event-driven, randomized, double-blind, placebo-controlled trial designed to examine the acute and chronic effects of a fixed dose (30 m/day) of tolvaptan [88]. Tolvaptan induced normalization of serum sodium. However, its use did not show a significant reduction in all-cause mortality, readmission rates in patients with Na <135 while indicated an improved survival free from cardiovascular death or readmission in patients with Na <130 [89, 90]. A post hoc analysis of the EVEREST database showed that in the hyponatremia subgroup tolvaptan was associated with greater weight loss, greater likelihood of normalization of serum sodium, less likelihood of having a decrease to a more severe level of hyponatremia; and greater relief of dyspnea,
with no effects on long-term outcomes [90]. The Targeting Acute Congestion with Tolvaptan in Congestive Heart Failure (TACTICS-HF) trial showed no improvement in dyspnea relief or long-term outcomes despite greater weight loss and fluid loss [91]. At higher doses of 60 to 90 mg/day, Tolvaptan has shown a non-statistically significant increase in adverse effects, and renal failure [92]. Tolvaptan has been approved in the US for patients with clinically significant hypervolemic and euvolemic hyponatremia with a serum sodium of <125, who did not respond to fluid restriction and diuretics [56, 57].

4.6. Conivaptan

Conivaptan is a V1A and V2-receptor blocker that is administered intravenously [64]. The hemodynamic effects of conivaptan have been evaluated in small studies with chronic stable HF patients on standard medical treatment [64]. The addition of conivaptan to furosemide showed an increase in urine volumes, as well as urine sodium excretion [93]; pulmonary capillary wedge pressure and right atrial pressure showed a decrease [94]. Despite potentially favorable tolerability profile of conivaptan in these small studies [64, 95, 96], it is still currently suggested that conivaptan should not be used in patients with HF; given there is no strong evidence suggesting benefits as treatment for HF [96]. In addition, significant hypotension can occur in patients receiving conivaptan therapy [97, 98].

4.7. Lixivaptan

Lixivaptan is an oral, V2-receptor antagonist [64]. Lixivaptan’s safety and effects in hospitalized patients with worsening HF and hyponatremia are currently being evaluated in a randomized, double-blind, placebo-controlled trial [99]. The BALANCE (Treatment of Hyponatremia Based on Lixivaptan in NYHA Class III/IV Cardiac Patient Evaluation) study is enrolling only patients with HF hyponatremia and utilizes tailored therapeutic dosing [99]. In addition to assessing whether Lixivaptan can correct hyponatremia, The Balance study will assess improvement in cognitive function and clinical outcomes in HF patients [99]. Recruitment status has been completed. However, the publication of results is currently awaited [100]. In general, there is no strong evidence that vaptans improve outcomes in HF, and current guidelines recommend considering them (IIb) only in patients hospitalized with volume overload, with persistent severe and who are at risk for or having active cognitive symptoms despite water restriction [101].

5. FUTURE DIRECTIONS

In recent years, many risk prediction models combining clinical models with biomarkers have emerged to facilitate prognosis assessment of HF patients in either reduced or preserved ejection fraction in different settings [102-113]. Since hyponatremia is independently associated with adverse clinical outcomes in patients with HF [103-105], a number of predictor models incorporating serum sodium have been developed [106-109] such as the Heart Failure Survival Score (HFSS) [107], the Seattle Heart Failure Model (SHFM) [108], and the metabolic exercise test data combined with cardiac and kidney indexes [106]. While these models require further external validation on their performance [102], these predictor models suggest the usefulness of serum sodium assessment in clinical care for patients with HF. In the era of big data, implementing sophisticated analytical techniques such as artificial intelligence to analyze serum sodium from multiple EHRs may be useful [114-116].

Hyponatremia in patients with HF remains a challenge for clinicians, and available treatment options are limited. Ongoing studies are still underway to determine the utility of vasopressin receptor antagonists whether they have an impact on long-term outcomes [109]. Currently, there is ongoing randomized controlled trial NCT02183792, The Aquaresis Utility for Hyponatremic Acute Heart Failure Study (AQUA-HF), comparing the effects of tolvaptan-based aquaretic regimen versus furosemide infusion in acute HF with hyponatremia. The findings from this study will potentially provide more information on the efficacy and safety outcomes of a tolvaptan-based diuretic regimen, compared to a furosemide-based regimen in hyponatremic acute HF patients.

CONCLUSION

Pathophysiology of hyponatremia in HF patients is often multifactorial. Clinical and biochemical evaluation often helps in differentiating dilutional from depletional hyponatremia to guide treatment strategies. The presence of hyponatremia in patients with HF is associated with increased risk of morbidity and mortality reflecting the severity of HF, or a direct effect of hyponatremia. Hyponatremia with severe symptoms is a medical emergency, and due to the high risk of neurologic sequelae, should be treated regardless of the patient’s volume status. Currently, fluid restriction and loop diuretics remain cornerstones of dilutional hyponatremia management in patients with HF. Although V2 receptor antagonists are considered as potentially promising treatments for refractory hypervolemic hyponatremia in patients with HF, resulting in improvement in serum sodium, improved dyspnea, negative fluid balance, and weight loss, these potential short-term effects have not translated in improvements in long-term clinical outcomes and require future studies.

AUTHORS’ CONTRIBUTIONS

All authors had access to the data and a role in writing the manuscript.

CONSENT FOR PUBLICATION

Not applicable.

FUNDING

None.

CONFLICT OF INTEREST

The authors declare no conflict of interest, financial or otherwise.
ACKNOWLEDGEMENTS

Declared none.

REFERENCES

[1] Akintayo E, Biasoulin A, Egbe A, et al. National trends in admission and in-hospital mortality of patients with heart failure in the united states (2001-2014). J Am Heart Assoc 2017; 6(12): pii: e006955.

[2] Agarwal SK, Wurck L, Quiribera M, et al. Temporal trends in hospitalization for acute decompensated heart failure in the united states, 1998-2011. Am J Epidemiol 2016; 183: 462-70.

[3] Ghali JK, Cooper R, Ford E. Trends in hospitalization rates for heart failure in the united states, 1973-1986. Evidence for increasing population prevalence. Arch Intern Med 1990; 150: 769-73.

[4] Mozaffarian D, Benjamin Emelia J, et al. Executive summary: Heart disease and stroke statistics-2016 update. Circulation 2016; 133: 447-54.

[5] Ambrosy AP, Fonarow GC, Butler J, et al. The global health and economic burden of hospitalizations for heart failure: Lessons learned from hospitalized heart failure registries. J Am Coll Cardiol 2014; 63: 1123-33.

[6] Heidenreich PA, Albert NM, Allen LA, et al. Forecasting the impact of heart failure in the united states: A policy statement from the American Heart Association. Circ Heart Fail 2013; 6: 606-19.

[7] Beath RW, Edwards PG. Neurohumoral abnormalities in heart failure: Impact of exercise training. Congest Heart Fail 2003; 9: 70-6.

[8] Jackson G, Gibbs CR, Davies MK, Lip GY. Apc of heart failure. Pathophysiology. BMJ 2000; 320: 167-70.

[9] Oster JR, Preston RA, Materson BJ. Fluid and electrolyte disorders in congestive heart failure. Semin Nephrol 1994; 14: 485-505.

[10] Gheorghiade M, Rossi JS, Coats A, et al. Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the escape trial. Arch Intern Med 2007; 167: 1998-2005.

[11] Verbrugge FH, Steels P, Grijten L, Nijst P, Tang WH, Mullens W. Hypernatremia in acute decompensated heart failure: Depletion versus dilution. J Am Coll Cardiol 2015; 65: 480-92.

[12] Holland-Bill L, Christiansen CF, Heide-Jorgensen U, et al. Hyponatremia and mortality risk: A danish cohort study of 279 508 acutely hospitalized patients. Eur J Endocrinol 2015; 173: 71-81.

[13] Waiker SS, Mount DB, Curhan GC. Mortality after hospitalization with mild, moderate, and severe hyponatremia. Am J Med 2009; 122: 857-65.

[14] Corona G, Giuliani C, Parenti G, et al. The economic burden of hyponatremia: Systematic review and meta-analysis. Am J Med 2016; 129: 823-35:e284.

[15] Omar HR, Charnigo R, Guglin M. Prognostic significance of discharge hyponatremia in heart failure patients with normal admission sodium (from the escape trial). J Am Coll Cardiol 2017; 120: 007-15.

[16] Adrogué HJ, Madias NE. Hyponatremia. N Engl J Med 2000; 342: 1581-9.

[17] Klein L, O’Connor CM, Leimberger JD, et al. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: Results from the outcomes of a prospective trial of intravenous milrinone for exacerbations of chronic heart failure (optime-chf) study. Circulation 2005; 111: 2454-60.

[18] Sato N, Gheorghiade M, Kajimoto K, et al. Hyponatremia and in-hospital mortality in patients admitted for heart failure (from the attend registry). Am J Cardiol 2013; 111: 1019-25.

[19] Binanay C, Calif RM, Hasselblad V, et al. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: The escape trial. JAMA 2005; 294: 1625-33.

[20] Lee SE, Lee HY, Cho HJ, et al. Clinical characteristics and outcome of acute heart failure in korea: Results from the korean acute heart failure registry (kohar). Korean Circ J 2017; 47: 341-53.

[21] Dunlap ME, Hauptman MP, Amin AN, et al. Current management of hyponatremia in acute heart failure: A report from the hyponatremia registry for patients with euvolemic and hypervolemic hypernatremia (hn registry). J Am Heart Assoc 2017; 6(8): pii: e005261.

[22] Upadhyay A, Jaber BL, Madias NE. Incidence and prevalence of hyponatremia. Am J Med 2006; 119: S30-5.

[23] Callahan MA, Do HT, Caplan DW, Yoon-Flannery K. Economic impact of hyponatremia in hospitalized patients: A retrospective cohort study. Postgrad Med 2009; 121: 186-91.

[24] Leimberger JD, Beeler PE, Bates DW. Impact of hyponatremia correction on the risk for 30-day readmission and death in patients with congestive heart failure. Am J Med 2016; 129: 836-42.

[25] Alabtain M, Brenner MJ, Nicklas JM, et al. Hyponatremia, cognitive function, and mobility in an outpatient heart failure population. Med Sci Moni 2016; 22: 4978-85.

[26] Romanovsky A, Bagshaw S, Rosen M. Hyponatremia and congestive heart failure: A marker of increased mortality and a target for therapy. Int J Nephrol 2011; 2011: 732746.

[27] De Vecchis R, Di Maio M, Di Biase G, Ariano C. Effects of hyponatremia normalization on the short-term mortality and rehospitalization in patients with recent acute decompensated heart failure: A retrospective study. J Clin Med 2016; 5: 92.

[28] Boscoe A, Paramore C, Verbalis JG. Cost of illness of hyponatremia in the United States. Cost Eff Resour Alloc 2006; 4: 10.

[29] Kazory A. Hyponatremia in heart failure: Revisiting pathophysiology and therapeutic strategies. Clin Cardiol 2010; 33: 322-9.

[30] Shepshelevich D, Schechter A, Calvarysky B, Diker-Cohen T, Rozen-Zvi B, Gaif-Grvili A. Medication-induced siadh: Distribution and characterization according to medication class. Br J Clin Pharmacol 2017; 83: 1801-7.

[31] Ramos-Levi AM, Duran Rodriguez-Hervada A, Mendez-Bailon M, Marco-Martinez J. Drug-induced hyponatremia: An updated review. Minerva Endocrinol 2014; 39: 1-12.

[32] Liams G, Millionis H, Elisas M. A review of drug-induced hyponatremia. Am J Kidney Dia 2008; 52: 144-53.

[33] Uretsky BF, Verbalis JG, Generalovich T, Valdes A, Reddy PS. Plasma vasopressin response to osmotic and hemodynamic stimuli in heart failure. Am J Physiol 1985; 248: H396-402.

[34] Oren RM. Hyponatremia in congestive heart failure. Am J Cardiol 2005; 95: 2-7.

[35] Mavani GP, DeVita MV, Michelis MF. A review of the nonpressor and nonantidiuretic actions of the hormone vasopressin. Front Med 2015; 2: 19.

[36] Filippatos TD, Elisas MS. Hyponatremia in patients with heart failure. World J Cardiol 2013; 5: 317-28.

[37] Goldsmith SR, Francis GS, Cowley AW, Jr. Arginine vasopressin and the renal response to water loading in congestive heart failure. Am J Cardiol 1986; 58: 295-9.

[38] Lee CR, Watkins ML, Patterson JH, et al. Vasopressin: A new target for the treatment of heart failure. Am Heart J 2003; 146: 9-18.

[39] Kala PR, Anker SD, Coats AJ. Water and sodium regulation in chronic heart failure: The role of natriuretic peptides and vasoactivity. Cardiovasc Res 2001; 51: 495-509.

[40] Goldsmith SR. Congestive heart failure: Potential role of arginine vasopressin antagonists in the therapy of heart failure. Congest Heart Fail 2002; 8: 251-6.

[41] Ronco C. Cardiorenal syndromes: Definition and classification. Contribut Nephrol 2010; 164: 33-8.

[42] Ronco C, Mccullough P, Anker SK, et al. Cardiorenal syndromes: Report from the consensus conference of the acute dialysis quality initiative. Eur J Heart 2010; 31: 703-11.

[43] Segall L, Nistor I, Covic A. Heart failure in patients with chronic kidney disease: A systematic integrative review. BioMed Res Int 2014; 2014: 937398.

[44] Kovesdy CP, Lott EH, Lu JL, et al. Hyponatremia, hypernatremia, and mortality in patients with chronic kidney disease with and without congestive heart failure. Circulation 2012; 125: 677-84.

[45] Fukushima A, Kimigawa S. Hyponatremia as a surrogate marker for optimal diuretic selection in acute heart failure. J Cardiol 2018; 71: 547-9.

[46] Liams G, Filippatos TD, Elisas MS. Thiazide-associated hyponatremia in the elderly: What the clinician needs to know. J Geriatr Cardiol 2016; 13: 175-82.

[47] Peacock WF, Costanzo MR, De Marco T, et al. Impact of intravenous loop diuretics on outcomes of patients hospitalized with acute decompensated heart failure: Insights from the adhe registry. Cardiology 2009; 113: 12-9.
[48] Felker GM, O'Connor CM, Braunwald E. Loop diuretics in acute decompensated heart failure: Necessary? Evil? A necessary evil? Circ Heart Fail 2009; 2: 56-62.

[49] Spiyal A. Diuretic-induced hyponatremia. Am J Nephrol 1999; 19: 447-52.

[50] Moravanski MP, Choi S, Hogg J, Anderson AS, Rich JD. Comparison of metolazone versus chlorothiazide in acute decompensated heart failure with diuretic resistance. Cardiovasc Therapeut 2015; 33: 42-9.

[51] Jentzer JC, DeWald TA, Hernandez AF. Combination of loop diuretics with thiazide-type diuretics in heart failure. J Am Coll Cardiol 2010; 56: 1527.

[52] Kroger N, Szuba J, Frenzel H. Metolazone in the treatment of advanced therapy-resistant dilated cardiomyopathy. Medizinische Klinik 1991; 86: 305-8.

[53] De Vecchis R, Ariano C, Esposito C, Giasi A, Cioppa C, Cantatore S. In right or biventricular chronic heart failure, addition of thiazides to loop diuretics to achieve a sequential blockade of the nephron is associated with an increased risk of dilutional hyponatremia: Results of a case-control study. Minerva Cardioangiol 2012; 60: 517-29.

[54] Goland S, Naugolny V, Kurot Z, Rozen I, Malnick S. Appropriateness and complications of the use of spironolactone in patients treated in a heart failure clinic. Eur J Intern Med 2011; 22: 424-7.

[55] Spasovski G, Vanholder R, Alloizio B, et al. Clinical practice guideline on diagnosis and treatment of hyponatremia. Eur J Endocrinol 2014; 170: G1-47.

[56] Spasovski G, Vanholder R, Alloizio B, et al. Hyponatremia diagnosis and treatment clinical practice guidelines. Nefrologia 2017; 37: 370-80.

[57] Hoom EJ, Zietse R. Diagnosis and treatment of hyponatremia: Compilation of the guidelines. J Am Soc Nephrol 2017; 28: 1340-9.

[58] Spasovski G, Vanholder R, Alloizio B, et al. Clinical practice guideline on diagnosis and treatment of hyponatremia. Nephrol Dial Transplant 2014; 29(Suppl 2): ii-i9.

[59] Watanabe T, Li H, Niu H, et al. Impact of compound hypertonic saline solution on decompensated heart failure. Int Heart J 2017; 58: 601-7.

[60] Lafrenière G, Beliveau P, Bégin JY, et al. Effects of hypertonic saline solution on body weight and serum creatinine in patients with acute decompensated heart failure. World J Cardiol 2013; 5: 517-8.

[61] Binkeli B, Strait KM, Dharmarajan K, et al. Intravenous fluids in acute decompensated heart failure. JACC Heart Fail 2015; 3: 127-33.

[62] Renneboog L, Musch W, Vandenbussche X, Manto MU, Decaux G. Malignant chronic hyponatremia is associated with falls, unsteadiness, and attention deficits. Am J Cardiol 2006; 97: 1064.

[63] Li P, Pasquale P, Vanholder R, et al. Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: Long-term effects. Am Heart J 2003; 145: 459-66.

[64] Vinod P, Krishnapapa V, Chauvin AM, Khare A, Raina R. Cardiorenal syndrome: Role of arginine vasopressin and vaptans in heart failure. Cardiol Res 2017; 8: 87-95.

[65] Lin TE, Adams FK, Jr., Patterson HH. Potential roles of vaptans in heart failure: Experience from clinical trials and considerations for optimizing therapy in target patients. Heart Fail Clin 2014; 10: 607-20.

[66] Hashim T, Sanam K, Revilla-Martinez M, et al. Clinical characteristics and outcomes of intravenous isotropic therapy in advanced heart failure. Circ Heart Fail 2015; 8: 880-6.

[67] Mebazaa A, Motiejaunaite J, Gayet E, et al. Long-term safety of intravenous cardiovascular agents in acute heart failure: Results from the European society of cardiology heart failure long-term registry. Eur J Heart Fail 2018; 20: 332-41.

[68] Vaduganathan M, Palka JS, Frenkel E, Butler J, Gheorghiade M. Serum chloride in heart failure: A salutary prognosis. Eur J Heart Fail 2016; 18: 669-71.

[69] Ghali JK, Tam SW. The critical link of hypervolemia and hyponatremia in heart failure and the potential role of arginine vasopressin antagonists. J Cardiac Fail 2010; 16: 419-31.

[70] Albert NM, Nutter B, Forney J, Sliniek E, Tang WH. A randomized controlled pilot study of outcomes of strict allowance of fluid therapy in hyponatremic heart failure (salt-hf). J Cardiac Fail 2013; 19: 1-9.

[71] Gheorghiade M, Gottlieb SS, Udelson JE, et al. Vasopressin vasopressin receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia. Am J Cardiol 2006; 97: 1064-7.

[72] Allida SM, Hayward CS, Newton PJ. Thirst in heart failure: What do we know so far? Curr Opin Support Palliat Care 2018; 12: 4-9.

[73] Sica DA. Hyponatremia and heart failure—treatment considerations. Congest Heart Fail 2006; 12: 55-60.

[74] Goldsmith SR. Current treatments and novel pharmacologic treatments for hyponatremia in congestive heart failure. Am J Cardiol 2005; 95: 14b-23b.

[75] Omar HR, Guglin M. Higher diuretic requirements in acute heart failure with admission hyponatremia versus normonatremia. Heart Lung Circ 2019; [Epub ahead of print].

[76] Omar HR, Guglin M. Etiology of discharge hyponatremia in decompensated heart failure and normal admission n+: Effect of diuretics. Eur J Intern Med 2018; 48: e15-e17.

[77] Gandhi S, Mosleh W, Myers RB. Hypertonic saline with furosemide for the treatment of acute congestive heart failure: A systematic review and meta-analysis. Int J Cardiol 2014; 173: 139-45.

[78] Paterna S, Parrinello G, Amato P, et al. Tolerability and efficacy of high-dose furosemide and small-volume hypertonic saline solution in refractory congestive heart failure. Adv Ther 1999; 16: 219-28.

[79] Okhurya A, Hirota S, Ando T, et al. Comparison of salt with low-dose furosemide and carperitide for treating acute decompensated heart failure: A single-center retrospective cohort study. Heart Vessels 2017; 32: 419-27.

[80] Kazory A. Haemodialysis, not ultrafiltration, can correct hyponatraemia in heart failure. Eur J Heart Fail 2010; 12: 208.

[81] Elisaf M, Theodorou J, Pappas C, Siamopoulos K. Successful treatment of hyponatremia with angiotensin-converting enzyme inhibitors in patients with congestive heart failure. Cardiology 1995; 86: 477-80.

[82] Balling L, Kober L, Schou M, Torg-Pedersen C, Gustafsson F. Efficacy and safety of angiotensin-converting enzyme inhibitors in patients with left ventricular systolic dysfunction and hyponatremia. J Cardiac Fail 2013; 19: 725-30.

[83] Oster JR, Materson BJ. Renal and electrolyte complications of congestive heart failure and effects of therapy with angiotensin-converting enzyme inhibitors. Arch Intern Med 1992; 152: 704-10.

[84] Baldasseroni S, Urso R, Orso F, et al. Relation between serum sodium levels and progression in outpatients with chronic heart failure: Neutral effect of treatment with beta-blockers and angiotensin-converting enzyme inhibitors: Data from the Italian network on congestive heart failure (in-chf database). J Cardiovasc Med 2011; 12: 723-31.

[85] Schumpelick WR, Briegel SB, Rule AD, Enders F, Lieske JC. Short-term tolvaptan increases water intake and effectively decreases urinary calcium oxalate, calcium phosphate and uric acid supersaturations. J Urol 2016; 195: 1476-81.

[86] Ali F, Guglin M, Vaitkevicius P, Ghali JK. Therapeutic potential of vaptans in ARF. Drugs 2007; 67: 847-58.

[87] Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin v2-receptor antagonist, for hyponatremia. N Engl J Med 2006; 355: 2099-112.

[88] Konstam MA, Gheorghiade M, Burnett JC, Jr., et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: The everest outcome trial. JAMA 2007; 297: 1319-31.

[89] McGreal K, Budhiraja P, Jain N, Yu AS. Current challenges in the evaluation and management of hyponatremia. Kidney Dis 2016; 2: 56-63.

[90] Hauptman PJ, Burnett J, Gheorghiade M, et al. Molecular causes of patients with hyponatremia and decompensated systolic heart failure and the effect of vaptans on vasopressor receptor antagonism with tolvaptan. J Cardiac Fail 2013; 19: 390-7.

[91] Felker GM, Mentz RJ, Cole RT, et al. Efficacy and safety of tolvaptan in patients hospitalized with acute heart failure. J Am Coll Cardiol 2017; 69: 1399-406.

[92] Wu MY, Chen TT, Chen YC, et al. Effects and safety of oral tolvaptan in patients with congestive heart failure: A systematic review and network meta-analysis. PLoS One 2017; 12: e0184380.
Hyponatremia in Heart Failure

[93] Goldsmith SR, Gilbertson DT, Mackedanz SA, Swan SK. Renal effects of conivaptan, furosemide, and the combination in patients with chronic heart failure. J Cardiac Fail 2011; 17: 982-9.

[94] Udelson JE, Smith WB, Hendrix GH, et al. Acute hemodynamic effects of conivaptan, a dual v1a and v(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 2001; 104: 2417-23.

[95] Annane D, Decaux G, Smith N. Efficacy and safety of oral conivaptan, a vasopressin-receptor antagonist, evaluated in a randomized, controlled trial in patients with euvolemic or hypervolemic hyponatremia. Am J Med Sci 2009; 337: 28-36.

[96] Cajaiba MM, Parks WT, Fuhrer K, Randhawa PS. Evaluation of human polyomavirus bk as a potential cause of villitis of unknown etiology and spontaneous abortion. J Med Virol 2011; 83: 1031-3.

[97] Der-Nigoghossian C, Lesch C, Berger K. Effectiveness and tolerability of conivaptan and tolvaptan for the treatment of hyponatremia in neurocritically ill patients. Pharmacotherapy 2017; 37: 528-34.

[98] Izumi Y, Miura K, Iwao H. Therapeutic potential of vasopressin receptor antagonists in heart failure. J Pharmacol Sci 2014; 124: 1-6.

[99] Abraham WT, Aranda JM, Boehmer JP, et al. Rationale and design of the treatment of hyponatremia based on lixivaptan in nyha class III/IV cardiac patient evaluation (the balance) study. Clin Transl Sci 2010; 3: 249-53.

[100] Fløgstad T, Traavik T, Kristiansen BE. Age-dependent prevalence of BK virus IgG and IgM antibodies measured by enzyme-linked immunosorbent assays (ELISA). J Hygiene 1986; 96: 523-8.

[101] Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: A report of the American college of cardiology foundation/American heart association task force on practice guidelines. J Am Coll Cardiol 2013; 62: e147-239.

[102] Dourmouras BS, Lee DS, Levy WC, Alca BA. An appraisal of biomarker-based risk-scoring models in chronic heart failure: Which one is best? Curr Heart Fail Rep 2018; 15: 24-36.

[103] Hamaguchi S, Kinugawa S, Tsuchihashi-Makaya M, et al. Hyponatremia is an independent predictor of adverse clinical outcomes in hospitalized patients due to worsening heart failure. J Cardiol 2014; 63: 182-8.

[104] Yoo BS, Park JJ, Choi DJ, et al. Prognostic value of hyponatremia in heart failure patients: An analysis of the clinical characteristics and outcomes in the relation with serum sodium level in asian patients hospitalized for heart failure (coast) study. Korean J Intern Med 2015; 30: 460-70.

[105] Lu DY, Cheng HM, Cheng YL, et al. Hyponatremia and worsening sodium levels are associated with long-term outcome in patients hospitalized for acute heart failure. J Am Heart Assoc 2016; 5: e002668.

[106] Agostoni P, Corra U, Cattadori G, et al. Metabolic exercise test data combined with cardiac and kidney indexes, the medci score: A multiparametric approach to heart failure prognosis. Int J Cardiol 2013; 167: 2710-8.

[107] Aaronson KD, Schwartz JS, Chen TM, Wong KL, Goin JE, Mancini DM. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation 1997; 95: 2660-7.

[108] Levy WC, Mozaffarian D, Linker DT, et al. The seattle heart failure model: Prediction of survival in heart failure. Circulation 2006; 113: 1424-33.

[109] Oh C, Chang HJ, Sung JM, et al. Prognostic estimation of advanced heart failure with low left ventricular ejection fraction and wide qrs interval. Korean Circ J 2012; 42: 659-67.

[110] Alba AC, Walter SD, Guyatt GH, et al. Predicting survival in patients with heart failure with an implantable cardioverter defibrillator: The heart failure meta-score. J Cardiac Fail 2018; 24: 735-45.

[111] Krittanawong C, Kukin ML. Current management and future directions of heart failure with preserved ejection fraction: A contemporary review. Curr Treat Options Cardiovasc Med 2018; 20: 28.

[112] Omar HR, Guglin M. Rise of first follow-up sodium in patients hospitalized with acute heart failure is associated with better outcomes. Int J Cardiol 2018; 269: 201-6.

[113] Omar HR, Guglin M. Community acquired versus hospital acquired hyponatremia in acute heart failure: Association with clinical characteristics and outcomes. Int J Cardiol 2016; 225: 247-9.

[114] Krittanawong C, Zhang H, Wang Z, Aydar M, Kitai T. Artificial intelligence in precision cardiovascular medicine. J Am Coll Cardiol 2017; 69: 2657-64.

[115] Krittanawong C, Johnson KW, Hershman SG, Tang WHW. Big data, artificial intelligence, and cardiovascular precision medicine. Expert Rev Precis Med Drug Dev 2018; 3: 305-17.

[116] Krittanawong C, Johnson KW, Rosenson RS, et al. Deep learning for cardiovascular medicine: A practical primer. Eur Heart J 2019; doi:10.1093/eurheartj/ehz056. [Epub ahead of print]

[117] Ronco C, Haapiö M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome. J Am Coll Cardiol 2008; 52: 1527-39.

[118] Aliti GB, Rabelo ER, Clausnell N, Rohde LE, Biolo A, Beck-da-Silva L. Aggressive fluid and sodium restriction in acute decompensated heart failure: A randomized clinical trial. JAMA Intern Med 2013; 173: 1058-64.

[119] Gheorghiade M, Konstam MA, Burnett JC, Jr., et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: The everest clinical status trial. JAMA 2007; 297: 1332-43.

[120] Gheorghiade M, Gattis WA, O’Connor CM, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: A randomized controlled trial. JAMA 2004; 291: 1963-71.

[121] Ghali JK, Koren MJ, Taylor JR, et al. Efficacy and safety of oral conivaptan: A v1a/v2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. J Clin Endocrinol Metab 2006; 91: 2145-52.

[122] Zeltser D, Rosansky S, van Rensburg H, Verbalis JG, Smith N. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia. Am J Nephrol 2007; 27: 447-57.

[123] Konstam MA, Kiernan M, Chandler A, et al. Short-term effects of tolvaptan in patients with acute heart failure and volume overload. J Am Coll Cardiol 2017; 69: 1409-19.